Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 6/20 | 0.57 |
| ▸ | MMP2 | P08253 | 5/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | SCN1A | P35498 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 1/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662863 | 0.88 | MMP2 (0.57) | MMP9MMP2CYP2C9BLMPMP22 | |
| SCHEMBL6446699 | 0.83 | MMP2 (0.66) | MMP9MMP2MMP3MMP8MMP13 | |
| SCHEMBL7477539 | 0.78 | MMP2 (0.41) | MMP9MMP2ALDH1A1KCNH2MMP3 | |
| SCHEMBL8265816 | 0.77 | MMP2 (0.54) | MMP9MMP2CYP2C9BLMPMP22 | |
| SCHEMBL713351 | 0.76 | MMP9 (0.61) | MMP9MMP2CYP2C9BLMPMP22 | |
| SCHEMBL1861823 | 0.74 | MMP9 (0.59) | MMP9MMP2CYP2C9BLMPMP22 | |
| SCHEMBL3207324 | 0.74 | MMP9 (0.59) | MMP9MMP2CYP2C9BLMPMP22 | |
| SCHEMBL3195931 | 0.74 | MMP9 (0.59) | MMP9MMP2CYP2C9BLMPMP22 | |
| SCHEMBL7472025 | 0.74 | MMP2 (0.47) | MMP9MMP2MAPTMMP3MMP8 | |
| SCHEMBL77738 | 0.73 | MMP2 (1.00) | MMP9MMP2CYP2C9BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305026-B1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | NOVUSPHARMA SPA (IT) | 2009-05-13 | — | — | EP | disclosed |
| US-20080113993-A1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | VIA ARIOSTO, 23 (IT) | 2008-05-15 | — | — | US | disclosed |
| CN-1318406-C | New barbituric acid derivatives, processes for their prodn. and pharmaceutical agent contg. same | BOEHRINGER MANNHEIM GMBH (DE) | 2007-05-30 | — | — | CN | disclosed |
| US-20030229108-A1 | Barbituric acid analogs as therapeutic agents | NOVUSPHARMA S.P.A. (IT) | 2003-12-11 | — | — | US | disclosed |
| CN-1433312-A | Barbituric acid analogs as therapeutic agents | NOWISS MEDICINE S P A (IT) | 2003-07-30 | — | — | CN | disclosed |
| EP-1305026-A2 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | Novuspharma S.p.A. (IT) | 2003-05-02 | — | — | EP | disclosed |
| US-6472396-B1 | Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds | ROCHE DIAGNOSTICS GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| EP-0869947-B1 | BARBITURIC ACID DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001093841-A2 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | NOVUSPHARMA S.P.A. (IT) | 2001-12-13 | — | — | WO | disclosed |
| US-6110924-A | MATRIX METALLOPROTEASE INHIBITORS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-08-29 | — | — | US | disclosed |
| CN-1209123-A | New barbituric acid derivatives, processes for their prodn. and pharmaceutical agent contg. same | BOEHRINGER MANNHEIM GMBH (DE) | 1999-02-24 | — | — | CN | disclosed |
| EP-0869947-A1 | NEW BARBITURIC ACID DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023465-A1 | NEW BARBITURIC ACID DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229108-A1 | Barbituric acid analogs as therapeutic agents | HIF1AN, HIF1A, VHL | MMP9 1460/4885MMP2 1450/4885CYP2C9 3738/4885 |
| US-20080113993-A1 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | HIF1A, HIF1AN, PDGFA | MMP9 1986/4885MMP2 1803/4885CYP2C9 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.